{
  "success": true,
  "pagesUsed": [
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    14,
    15,
    16,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "claude-opus-4-5",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ramucirumab SC",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Subcutaneous formulation of ramucirumab for investigation in participants with cancer",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Paclitaxel",
        "role": {
          "code": "Concomitant Medication",
          "codeSystem": "USDM",
          "decode": "Concomitant Medication"
        },
        "instanceType": "StudyIntervention",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants",
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "FOLFIRI",
        "role": {
          "code": "Concomitant Medication",
          "codeSystem": "USDM",
          "decode": "Concomitant Medication"
        },
        "instanceType": "StudyIntervention",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Erlotinib",
        "role": {
          "code": "Concomitant Medication",
          "codeSystem": "USDM",
          "decode": "Concomitant Medication"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral EGFR tyrosine kinase inhibitor administered with ramucirumab SC in eligible participants",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Docetaxel",
        "role": {
          "code": "Concomitant Medication",
          "codeSystem": "USDM",
          "decode": "Concomitant Medication"
        },
        "instanceType": "StudyIntervention",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants",
        "administrationIds": [
          "admin_5"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ramucirumab SC",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Solution",
          "codeSystem": "USDM",
          "decode": "Solution"
        },
        "strength": "Various (350 mg, 700 mg, 875 mg, 1750 mg)",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Cohort A - Loading Dose",
        "instanceType": "Administration",
        "dose": "700 mg",
        "doseFrequency": "Once (Day 1)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Single dose"
      },
      {
        "id": "admin_2",
        "name": "Cohort A - Maintenance Dose",
        "instanceType": "Administration",
        "dose": "350 mg",
        "doseFrequency": "Once weekly (QW)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Until disease progression or discontinuation"
      },
      {
        "id": "admin_3",
        "name": "Sub-Cohort B1 - Maintenance Dose",
        "instanceType": "Administration",
        "dose": "875 mg",
        "doseFrequency": "Once weekly (QW)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Starting Week 1, no loading dose"
      },
      {
        "id": "admin_4",
        "name": "Sub-Cohort B2 - Loading Dose",
        "instanceType": "Administration",
        "dose": "1750 mg (maximum)",
        "doseFrequency": "Once (Day 1)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Single dose via SC infusion pump at approximately 0.25 ml/min"
      },
      {
        "id": "admin_5",
        "name": "Sub-Cohort B2 - Maintenance Dose",
        "instanceType": "Administration",
        "dose": "875 mg (maximum)",
        "doseFrequency": "Once weekly (QW)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Starting Week 2 (Cycle 1 Day 8)"
      },
      {
        "id": "admin_6",
        "name": "Sub-Cohort B3 - Loading Dose (Optional)",
        "instanceType": "Administration",
        "dose": "<1750 mg",
        "doseFrequency": "Once (Day 1)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Single dose, dose adjusted based on PK/safety data"
      },
      {
        "id": "admin_7",
        "name": "Sub-Cohort B3 - Maintenance Dose (Optional)",
        "instanceType": "Administration",
        "dose": "<875 mg",
        "doseFrequency": "Once weekly (QW)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Dose adjusted based on PK/safety data"
      },
      {
        "id": "admin_8",
        "name": "Cohort C - Dosing Regimen",
        "instanceType": "Administration",
        "dose": "Same as Cohort B (determined by PK/safety objectives)",
        "doseFrequency": "Once weekly (QW) with loading dose",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Until disease progression or discontinuation"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ramucirumab",
        "instanceType": "Substance",
        "description": "Human receptor-targeted monoclonal antibody that specifically binds VEGF Receptor 2"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 5,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ramucirumab SC",
        "role": "Investigational Product",
        "description": "Subcutaneous formulation of ramucirumab for investigation in participants with cancer"
      },
      {
        "name": "Paclitaxel",
        "role": "Concomitant Medication",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants"
      },
      {
        "name": "FOLFIRI",
        "role": "Concomitant Medication",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants"
      },
      {
        "name": "Erlotinib",
        "role": "Concomitant Medication",
        "description": "Oral EGFR tyrosine kinase inhibitor administered with ramucirumab SC in eligible participants"
      },
      {
        "name": "Docetaxel",
        "role": "Concomitant Medication",
        "description": "Combination anti-cancer treatment administered with ramucirumab SC in eligible participants"
      }
    ],
    "products": [
      {
        "name": "Ramucirumab SC",
        "doseForm": "Solution for subcutaneous injection/infusion",
        "strength": "Various (350 mg, 700 mg, 875 mg, 1750 mg)",
        "manufacturer": "Eli Lilly"
      }
    ],
    "substances": [
      {
        "name": "Ramucirumab",
        "description": "Human receptor-targeted monoclonal antibody that specifically binds VEGF Receptor 2"
      }
    ],
    "administrations": [
      {
        "name": "Cohort A - Loading Dose",
        "dose": "700 mg",
        "frequency": "Once (Day 1)",
        "route": "Subcutaneous",
        "duration": "Single dose"
      },
      {
        "name": "Cohort A - Maintenance Dose",
        "dose": "350 mg",
        "frequency": "Once weekly (QW)",
        "route": "Subcutaneous",
        "duration": "Until disease progression or discontinuation"
      },
      {
        "name": "Sub-Cohort B1 - Maintenance Dose",
        "dose": "875 mg",
        "frequency": "Once weekly (QW)",
        "route": "Subcutaneous",
        "duration": "Starting Week 1, no loading dose"
      },
      {
        "name": "Sub-Cohort B2 - Loading Dose",
        "dose": "1750 mg (maximum)",
        "frequency": "Once (Day 1)",
        "route": "Subcutaneous infusion",
        "duration": "Single dose via SC infusion pump at approximately 0.25 ml/min"
      },
      {
        "name": "Sub-Cohort B2 - Maintenance Dose",
        "dose": "875 mg (maximum)",
        "frequency": "Once weekly (QW)",
        "route": "Subcutaneous",
        "duration": "Starting Week 2 (Cycle 1 Day 8)"
      },
      {
        "name": "Sub-Cohort B3 - Loading Dose (Optional)",
        "dose": "<1750 mg",
        "frequency": "Once (Day 1)",
        "route": "Subcutaneous infusion",
        "duration": "Single dose, dose adjusted based on PK/safety data"
      },
      {
        "name": "Sub-Cohort B3 - Maintenance Dose (Optional)",
        "dose": "<875 mg",
        "frequency": "Once weekly (QW)",
        "route": "Subcutaneous",
        "duration": "Dose adjusted based on PK/safety data"
      },
      {
        "name": "Cohort C - Dosing Regimen",
        "dose": "Same as Cohort B (determined by PK/safety objectives)",
        "frequency": "Once weekly (QW) with loading dose",
        "route": "Subcutaneous",
        "duration": "Until disease progression or discontinuation"
      }
    ],
    "devices": []
  }
}